Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | PRODUCT CODE: 1874663

Cover Image

PUBLISHER: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | PRODUCT CODE: 1874663

Erythropoietin Drugs

PUBLISHED:
PAGES: 179 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5850
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Erythropoietin Drugs Market to Reach US$17.3 Billion by 2030

The global market for Erythropoietin Drugs estimated at US$13.4 Billion in the year 2024, is expected to reach US$17.3 Billion by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Epoetin-alfa, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$9.2 Billion by the end of the analysis period. Growth in the Darbepoetin-alfa segment is estimated at 4.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.7 Billion While China is Forecast to Grow at 4.0% CAGR

The Erythropoietin Drugs market in the U.S. is estimated at US$3.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.7 Billion by the year 2030 trailing a CAGR of 4.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.2% and 3.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global Erythropoietin Drugs Market - Unveiling Trends & Growth Accelerators

Why Are Erythropoietin Drugs Critical in Modern Healthcare?

Erythropoietin (EPO) drugs play a pivotal role in the treatment of anemia associated with chronic kidney disease (CKD), cancer, and other medical conditions that impair red blood cell production. These drugs mimic the natural hormone erythropoietin, which is primarily produced by the kidneys and stimulates bone marrow to generate red blood cells. By increasing red blood cell counts, erythropoietin drugs help improve oxygen delivery to tissues, reducing fatigue and enhancing overall patient well-being. Over the years, their usage has expanded beyond nephrology to include oncology, neurology, and even sports medicine, making them one of the most versatile biologic drugs in modern medicine.

The demand for erythropoietin drugs has surged due to the rising prevalence of CKD and cancer-related anemia, particularly in aging populations. Additionally, patients undergoing chemotherapy often experience severe anemia, necessitating the use of EPO drugs to mitigate treatment-related side effects. With advancements in biotechnology, newer formulations such as darbepoetin alfa and methoxy polyethylene glycol-epoetin beta have been developed, offering longer half-lives and reduced dosing frequencies. Furthermore, biosimilar erythropoietin drugs have gained significant traction, providing cost-effective alternatives to branded biologics and expanding accessibility for patients worldwide. As the global burden of anemia-related diseases continues to grow, erythropoietin drugs remain a cornerstone of effective anemia management.

How Are Innovations Transforming the Erythropoietin Drug Market?

Innovation in erythropoietin drugs has been driven by the need for more efficient, long-lasting, and cost-effective treatments. One of the most significant advancements is the development of second-generation and third-generation EPO drugs, which feature extended half-lives and improved efficacy. For example, darbepoetin alfa has been engineered with additional carbohydrate chains, allowing for less frequent dosing compared to traditional recombinant human erythropoietin (rHuEPO). Similarly, methoxy polyethylene glycol-epoetin beta offers prolonged activity, reducing the need for frequent injections and improving patient compliance. These next-generation drugs are revolutionizing anemia treatment, particularly for CKD and cancer patients who require long-term therapy.

Another major breakthrough is the rise of erythropoiesis-stimulating agents (ESAs) that work through alternative mechanisms, such as hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs). These oral drugs, unlike traditional EPO injections, stimulate endogenous erythropoietin production, mimicking the body’s natural response to low oxygen levels. This innovation has opened new treatment avenues, especially for patients with CKD who are unable to tolerate injectable therapies. Additionally, the growing availability of biosimilar EPO drugs has significantly disrupted the market by offering affordable options without compromising efficacy. As governments and healthcare providers seek cost-effective treatment alternatives, biosimilars are expected to gain further market share, making EPO therapy more accessible worldwide.

Which Therapeutic Areas Are Driving the Demand for Erythropoietin Drugs?

Erythropoietin drugs have established a strong presence across multiple therapeutic areas, with nephrology and oncology leading the market. CKD remains the largest segment, as anemia is a common complication in patients with declining kidney function. With the increasing incidence of diabetes and hypertension-two major risk factors for CKD-the demand for erythropoietin drugs continues to rise. Patients undergoing dialysis or kidney transplants also rely heavily on EPO therapy to maintain adequate red blood cell levels, preventing severe anemia-related complications. The nephrology sector’s reliance on these drugs has solidified their place as a critical component of CKD management.

Oncology is another key driver of erythropoietin drug demand, as cancer patients frequently develop anemia due to chemotherapy-induced bone marrow suppression. By using EPO drugs, oncologists can reduce the need for blood transfusions, improving patients' quality of life and supporting continuous cancer treatment. Additionally, erythropoietin drugs are gaining traction in other medical fields, including neurology, where they are being explored for neuroprotective effects in stroke and neurodegenerative diseases. Some studies suggest that EPO drugs may enhance cognitive recovery following brain injuries, opening new possibilities for their application. As research continues to uncover novel therapeutic benefits, erythropoietin drugs are expected to expand into emerging medical areas beyond their traditional use in anemia management.

What’s Driving the Rapid Growth of the Erythropoietin Drugs Market?

The growth in the global erythropoietin drugs market is driven by several factors, including the increasing prevalence of chronic diseases such as CKD, cancer, and diabetes. As the global population ages, the incidence of these conditions continues to rise, fueling the demand for effective anemia treatments. Advances in biologic drug development, particularly in the production of long-acting EPO formulations, have further propelled market expansion by improving treatment adherence and reducing dosing frequency. The surge in biosimilar approvals has also played a crucial role in driving market growth, as healthcare systems worldwide seek cost-effective alternatives to branded biologics. Biosimilars have significantly reduced treatment costs while maintaining comparable efficacy, expanding accessibility in emerging markets.

Regulatory advancements and government support for anemia treatment programs have further contributed to the market’s upward trajectory. Many countries have introduced reimbursement policies and national anemia management programs that promote the use of erythropoietin drugs in public healthcare systems. Additionally, the increasing adoption of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) as an alternative to injectable ESAs is diversifying treatment options and attracting investments from pharmaceutical companies. The growing emphasis on personalized medicine, where EPO therapies are tailored to individual patient needs, is also expected to enhance treatment outcomes and market penetration. With ongoing research, new therapeutic indications, and continuous advancements in biotechnology, the global erythropoietin drugs market is poised for sustained expansion, addressing the growing burden of anemia-related diseases worldwide.

SCOPE OF STUDY:

The report analyzes the Erythropoietin Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Epoetin-Alfa, Darbepoetin-Alfa, Epoetin-Beta, Other Drug Types); Application (Kidney Disorders, Hematology, Cancer, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 12 Featured) -

  • Amgen, Inc.
  • Biocon Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson Services, Inc.
  • Kyowa Kirin Co., Ltd.
  • Novartis AG
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • XTL Biopharmaceuticals Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP11849

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
    • Global Economic Update
    • Erythropoietin Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Anemia Associated with Chronic Kidney Disease Boosting Demand for Erythropoietin Drugs
    • Increasing Use of Erythropoietin in Cancer Treatment for Chemotherapy-induced Anemia
    • Expansion of Therapeutic Applications Beyond Anemia to Neuroprotection and Wound Healing
    • Growing Biosimilars Market Intensifying Competition Among Erythropoietin Manufacturers
    • Consumer Awareness and Increasing Healthcare Access in Emerging Markets
    • Integration of Artificial Intelligence in Clinical Trials for Faster Drug Development
    • Rising Demand for Erythropoietin Drugs in Sports Medicine and Doping
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Kidney Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Kidney Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Kidney Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Hematology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Epoetin-alfa by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Epoetin-alfa by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 15: World 15-Year Perspective for Epoetin-alfa by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Darbepoetin-alfa by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Darbepoetin-alfa by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 18: World 15-Year Perspective for Darbepoetin-alfa by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Epoetin-beta by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Epoetin-beta by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 21: World 15-Year Perspective for Epoetin-beta by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 24: World 15-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 25: World Erythropoietin Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Erythropoietin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Erythropoietin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Erythropoietin Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Erythropoietin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2015, 2025 & 2030
  • JAPAN
    • Erythropoietin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2015, 2025 & 2030
  • CHINA
    • Erythropoietin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2015, 2025 & 2030
  • EUROPE
    • Erythropoietin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Erythropoietin Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Erythropoietin Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Erythropoietin Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
  • FRANCE
    • Erythropoietin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2015, 2025 & 2030
  • GERMANY
    • Erythropoietin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Erythropoietin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Rest of Europe 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Erythropoietin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Asia-Pacific 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of World 15-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 101: Rest of World Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of World Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of World 15-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!